Elon Musk’s company has won clinical trial approval for a human brain implant
The US Food and Drug Administration (FDA) has approved Neuralink’s first human clinical trials, Reuters reports.
Neuralink has been operating since 2016, and is a subsidiary of Elon Musk’s company, which deals with the creation of implantable brain-computer interfaces. This is to help treat neurological diseases, including Alzheimer’s disease, dementia, and spinal cord injury. It can also be a way to communicate with artificial intelligence.
Reuters reports that since 2019, Elon Musk has announced human trial launches at least four times. The agency has learned informally that Neuralink applied for approval only once, in early 2022, and was denied. The FDA had doubts about the implanted lithium battery, the possibility of the device’s wires going into the brain, and the problem of safely removing them without damaging brain tissue.